Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) Shares Sold by Fifth Third Bancorp
Fifth Third Bancorp trimmed its position in Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) by 29.1% in the first quarter, according to its most recent disclosure with the SEC. The institutional investor owned 9,750 shares of the biotechnology company’s stock after selling 4,000 shares during the period. Fifth Third Bancorp’s holdings in Progenics Pharmaceuticals were worth $37,000 at the end of the most recent reporting period.
A number of other large investors have also recently bought and sold shares of the stock. SG Americas Securities LLC acquired a new position in Progenics Pharmaceuticals in the first quarter worth about $68,000. ARP Americas LP grew its stake in Progenics Pharmaceuticals by 98.0% in the first quarter. ARP Americas LP now owns 433,471 shares of the biotechnology company’s stock worth $1,647,000 after purchasing an additional 214,496 shares in the last quarter. Texas Permanent School Fund grew its stake in Progenics Pharmaceuticals by 24.4% in the first quarter. Texas Permanent School Fund now owns 73,562 shares of the biotechnology company’s stock worth $280,000 after purchasing an additional 14,449 shares in the last quarter. State of Alaska Department of Revenue grew its stake in Progenics Pharmaceuticals by 17.7% in the first quarter. State of Alaska Department of Revenue now owns 76,813 shares of the biotechnology company’s stock worth $291,000 after purchasing an additional 11,554 shares in the last quarter. Finally, Nuveen Asset Management LLC grew its stake in Progenics Pharmaceuticals by 0.7% in the fourth quarter. Nuveen Asset Management LLC now owns 649,525 shares of the biotechnology company’s stock worth $3,306,000 after purchasing an additional 4,835 shares in the last quarter. Institutional investors and hedge funds own 66.52% of the company’s stock.
PGNX has been the subject of a number of research reports. BidaskClub downgraded Progenics Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Tuesday, May 5th. Zacks Investment Research raised shares of Progenics Pharmaceuticals from a “hold” rating to a “buy” rating and set a $4.25 target price on the stock in a report on Tuesday. Finally, ValuEngine raised shares of Progenics Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Thursday, April 2nd. One investment analyst has rated the stock with a sell rating and five have assigned a buy rating to the company’s stock. Progenics Pharmaceuticals has an average rating of “Buy” and a consensus target price of $9.42.
Progenics Pharmaceuticals (NASDAQ:PGNX) last released its quarterly earnings results on Thursday, May 7th. The biotechnology company reported ($0.19) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.22) by $0.03. The company had revenue of $6.25 million for the quarter. Progenics Pharmaceuticals had a negative return on equity of 129.46% and a negative net margin of 180.28%.
Progenics Pharmaceuticals Profile
Progenics Pharmaceuticals, Inc, an oncology company, develops, manufactures, and commercializes pharmaceutical products and other technologies to target, diagnose, and treat cancer cancer in the United States and internationally. The company's product candidates include Azedra, a radiotherapeutic product candidate for the treatment of iobenguane scan positive, unresectable, and locally advanced or metastatic pheochromocytoma or paraganglioma for adult and pediatric patients; PyL, a clinical-stage fluorinated prostate specific membrane antigen (PSMA)-targeted PET/CT imaging agent for prostate cancer; and 1095, a PSMA-targeted Iodine-131 labeled small molecule, which is in Phase II clinical trial for the treatment of metastatic castration-resistant prostate cancer.
Featured Story: What is the Russell 2000 Index?
Receive News & Ratings for Progenics Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Progenics Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.